Plasma Fractionation Market worth USD xx million by 2023

Posted by venkatakiran on October 10th, 2019

Plasma Fractionation Market Size and Growth Rate:

 

The Global Plasma Fractionation Market was valued around US$ 23.6 Bn by 2018 and growing at a significant CAGR of 5.5% over next seven years 2019-2023 due to increasing incidences of blood and immune disorders

 

Plasma Fractionation Market Growth Drivers and Restraints:

The global plasma fractionation market accounted for US$ 23.6 Bn in 2018 and burgeoning over the forthcoming years. Growing occurrence of respiratory diseases and AATD driving the uptake of alpha-1-antitrypsin, increasing incidences of blood and immune disorders, growing use of immunoglobulins in various therapeutic areas and consistent investments in medicine and R&D are some key factors influencing the market growth. However, factors such as high cost & limited reimbursement and stringent government regulations are restricting the market growth.

Browse More Insights of the report @https://www.precisionbusinessinsights.com/market-reports/global-plasma-fractionation-market/

Albumin dominate the Global Plasma Fractionation Market

Based on product type, global plasma fractionation market is segmented into albumin, immunoglobulin, coagulation factor concentrates, protease inhibitors and other. Albumin held considerable market growth during estimated period. Albumin is a protein made by the liver. It makes up about 60% of the complete protein in the blood and plays many roles. This test measures the level of albumin in the blood.

Albumin preserves fluid from leaking out of blood vessels; nourishes tissues; and transports hormones, vitamins, drugs, and substances like calcium throughout the body. Levels of albumin may decrease, to a greater or lesser degree, when conditions interfere with its production by the liver, increase protein breakdown, increase protein loss via the kidneys, and/or expand plasma volume.

North America Leads the Global Plasma Fractionation market

 

PBI’s global plasma fractionation market report analyses the market in different regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. According to regional analysis. North America accounted for larger revenue share in global plasma fractionation market with considerable CAGR. The growth in this region can be attributed to growing geriatric population, increasing occurrence of respiratory diseases and increasing per capita healthcare spending. Also, U.S is the major contributor for the market growth in this region. In addition, Asia Pacific held considerable market share during estimated period owing to growing healthcare expenditure, increasing aging population together with rising cancer disease and rising lifestyle-related disorders.

Strategic New Product Launches are the Key Strategies Adopted by Market Players

 

Global plasma fractionation market further reveals that the key players increasingly adopting strategies such as launch of newer products, frequent product approvals, and long term alliance to improve market revenue share and gaining significant geographic presence across the region. For Instance, In September 2018, Grifols launched GamaSTAN immune globulin (human) for hepatitis A virus (HAV) and measles postexposure prophylaxis, and Prolastin-C Liquid [alpha-1 proteinase inhibitor, liquid] for the treatment of alpha-1 antitrypsin deficiency

Key player’s profiles in the report are Grifols S.A (Spain), CSL Ltd. (Australia), Shire (Ireland), Octapharma AG (Switzerland), Kedrion S.p.A (Italy), China Biologic Products, Inc. (China), Biotest AG (OGEL GmbH) (Germany), LFB S.A (France) and Sanquin (Netherlands).

Avail Sample of the report for more information @https://www.precisionbusinessinsights.com/request-sample?product_id=15896

Detailed Segmentation of Plasma Fractionation Market:

 

By Product Type                              

o     Albumin          

o     Immunoglobulin          

  • Intravenous immunoglobulin
  • Subcutaneous immunoglobulin
  • Others

o     CoagulationFactor Concentrates         

  • Factor viii
  • Factor ix
  • Factor xiii
  • Prothrombin complex concentrates
  • Von Willebrand factor (VWF)

o                 Protease Inhibitors        

o                 OtherPlasma Fractionation Products     

 

By Application                 

o     Neurology      

o     Haematology

o     Immunology 

o     Rheumatology             

o     Haemato-oncology    

o     Critical Care   

o     Pulmonology

o     Others             

 

By End User                       

o     Hospitals         

o     Clinics               

o     Academic Institutes   

o     Clinical Research Laboratories

 

By Geography

o     North America

o     Europe

o     Asia-Pacific

o     Latin America

o     Middle East and Africa (MEA)

About Us:

Precision Business Insights is one of the leading market research and management consulting firm, run by a group of seasoned and highly dynamic market research professionals with a strong zeal to offer high-quality insights.

Contact Us:

Shreya Paul

Senior Business Development Executive

Email @ shreya@precisionbusinessinsights.com

Call @ +1-866-598-1553

Precision Business Insights

Like it? Share it!


venkatakiran

About the Author

venkatakiran
Joined: September 16th, 2019
Articles Posted: 111

More by this author